NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.79 +0.77 (+0.99%) GOLD FUTURES
2,391.10 +31.20 (+1.32%) DOW
39,850.51 +292.40 (+0.74%) Bitcoin GBP
51,786.85 +3,304.47 (+6.82%)
Transgene SA (TRGNF)
| Previous close | 1.6200 |
| Open | 1.6200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.6200 - 1.6200 |
| 52-week range | 1.6200 - 2.1000 |
| Volume | |
| Avg. volume | 4 |
| Market cap | 163.382M |
| Beta (5Y monthly) | 0.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Transgene’s Combined General Meeting of May 15, 2024
Strasbourg, France, May 15, 2024, 05:45 p.m. CEST – The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held today (May 15, 2024) at 10:00 a.m. at the Company’s headquarters (400 boulevard Gonthier d’Andernach – Parc d’Innovation – 67400 Illkirch-Graffenstaden, France). The meeting was chaired by Alessandro Riva, Chairman and CEO, to approve the Company’s financial statements for the year ended December 31, 2023, and to vote on the other resolutions submitted
- GlobeNewswire
Transgene provides business and financial update for Q1 2024
TG4050: Exciting Phase I data presented at AACR 2024 demonstrating first signs of clinical benefit in adjuvant setting for head and neck cancer Phase II part of randomized trial to start in coming weeks New clinical data expected on TG4001, TG6050 and BT-001 in H2 2024 Financial visibility until Q4 2025 Strasbourg, France, May 14, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provi
- Globe Newswire
Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024
Strasbourg, France, April 24, 2024, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shareholders is available. The notice of meeting, comprising the agenda and the draft resolutions was published in the Bulletin des Annonces Légales Obligatoires (BALO) n° 42 of April 5, 2024. These notices include i
